International Validation of Two Non-motor Scales in PD (NFS and SPARK)

NCT04366804 · tracked via the Priya Life Science Spain tracker

Sponsor

Insel Gruppe AG, University Hospital Bern

Phase

Observational

Started

2020-12-03

Last updated

2025-04-13

Condition(s) studied

Parkinson's DiseaseNon-motor Symptoms

Study summary

The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).

Eligibility

Sex

ALL

Min age

30 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Written informed consent; 2. PD, according to the MDS criteria; 3. Age of participants \> 30 and \< 75 years; 4. Being fluent in the language in which the scales are applied. Exclusion Criteria: 1\. Presence of PD dementia (defined as MoCA score \< 24).

Primary outcome measure(s)

NFS score — 2 weeks (2 assessments in a time span of 2 weeks)
SPARK score — 2 weeks (2 assessments in a time span of 2 weeks)

Trial sites (8)

Facility	City	Region	Status
Centre hospitalier régional universitaire de Besançon	Besançon	France	Completed
Universitätsklinikum Carl Gustav Carus	Dresden	Germany	Completed
Aristotle University of Thessaloniki	Thessaloniki	Greece	Completed
Transilvania University	Brasov	Romania	Recruiting
Hospital Universitario Burgos	Burgos	Spain	Completed
Ruber International Hospital	Madrid	Spain	Completed
Insel Gruppe AG University Hospital Bern	Bern	Switzerland	Completed
King's College London	London	United Kingdom	Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Spain

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation Recruiting

Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake Recruiting

Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants Recruiting

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy Recruiting

Surgery for Recurrent Glioblastoma Recruiting

Other trials for the same condition

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease Recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Active, not recruiting

Prevent Cognitive Decline in GBA-associated Parkinson's Disease Starting soon

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04366804 on ClinicalTrials.gov ↗ ← All trials in Spain